Tuesday, 16 June 2026 02:10 PM
Advertorial
As more adults compare online GLP-1 weight loss programs in 2026, this Shed GLP-1 review explores how the telehealth platform is positioned for provider-guided care access, what patients should know about compounded and FDA-approved options, and which pricing, eligibility, and guarantee factors may influence the experience.
SOUTH JORDAN, UT / ACCESS Newswire / June 16, 2026 / ShedRx:
Shed GLP-1 Research 2026: Updated Guarantee, Foundayo Approval, the FDA's June 29 Compounding Deadline, and What to Verify Before Enrolling
Advertorial Disclosure: This is promotional content with affiliate links - if you enroll through a link in this article, a commission may be earned at no extra cost to you, per FTC 16 CFR Part 255. That relationship doesn't change what's written here. Shed is a telehealth platform; licensed healthcare providers make all prescribing decisions independently, and approval for treatment isn't guaranteed. Compounded GLP-1 medications are not FDA-approved finished drug products. Before starting any prescription treatment, talk to your own doctor.
The Short Version (read the rest when you're ready)
Shed connects you with independent licensed providers who evaluate whether GLP-1 treatment is right for you - they prescribe, Shed doesn't. As of June 10, 2026, their money-back guarantee got a significant update: it's now a 120-Day Guarantee with a 5% body-weight threshold instead of the old 9-month / 10% structure. They've added Foundayo® (orforglipron) - the first FDA-approved oral GLP-1 pill, approved April 2026. Pricing on their product pages starts from $199/month for some formats, but that's a starting-dose number - costs go up as your dose does, so confirm your actual cost at checkout. Three compounding pharmacies are named in their current Terms: Strive, Promise, and Foothills. And if you're considering any compounded GLP-1 program right now: the FDA's public comment deadline on proposed 503B compounding restrictions is June 29, 2026 - 13 days from today. The 503A patient-specific pathway is still legally active. But the regulatory landscape is changing. This review has the details.
Shed GLP-1 2026 Quick Verification Snapshot
As of June 2026, the following information was publicly disclosed on tryshed.com and in Shed's Terms and Conditions (effective date: June 10, 2026):
Platform operator: Shed Holdings, LLC - technology and administrative services only; does not prescribe, dispense, or sell medications
Prescribing: Independent, physician-owned or licensed professional entities and their affiliated licensed healthcare providers (the "Provider Group") - all prescribing decisions are made independently by licensed providers
Named compounding pharmacies (Terms §38): Strive Compounding Pharmacy (Gilbert, AZ), Promise Pharmacy (Palm Harbor, FL), Foothills Professional Pharmacy (Tempe, AZ)
GLP-1 Injection price reference: Some Shed product pages reference $199/month for compounded semaglutide injections at starting doses - actual cost varies by dose, format, and program selection
GLP-1 Liquid Drops price reference: $229/month referenced on Shed's product pages at starting doses; verify current pricing at checkout
GLP-1 Lozenges price reference: $199/month referenced on Shed's product pages; actual cost varies by dose and program
Month-to-month rate after multi-month term ends: $249/month (semaglutide), $349/month (tirzepatide) per Terms §13.1
Pricing verification: All prices listed are starting prices per Shed's published product pages as of June 2026. Actual cost varies by medication, dose, state, and checkout selection. Shed's promotional landing pages may display different pricing. Always confirm total cost at checkout on tryshed.com before enrolling.
Minimum commitment: Two months; auto-renewal after that
Cancellation window: 72 hours before next billing cycle; via Member Portal → My Treatments → Manage Subscription
Current guarantee: 120-Day Guarantee - 5% body weight loss or full refund of amounts paid during the 120-day period; four Member Commitments required
Prior guarantee (for members enrolled before June 10, 2026): Grandfathered 9-month / 10% guarantee remains in effect through end of their window
Membership fees: Non-refundable once treatment is approved; full refund if no Provider approval
LegitScript: Verification seal displayed on tryshed.com
Contact: [email protected] | 855-694-7433
Address: 10813 S River Front Pkwy, Ste 550, South Jordan, UT 84095
Compounded medication disclosure: Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing
FDA regulatory status (as of June 2026): On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List (Federal Register docket 2026-08552). Public comment period closes June 29, 2026. This is a proposed rule - not yet final. The 503A patient-specific compounding pathway, which is what licensed telehealth pharmacy partners use for individual prescriptions, remains legally active. Readers should confirm the current regulatory status of any compounded GLP-1 program before enrolling.
Buyer Takeaway: The single most important update since January is the guarantee. If a money-back backstop matters to your decision, what's currently in Shed's Terms is materially different from what most reviews describe. Read Section 16 before you use the guarantee as a reason to enroll - or a reason not to.
See current Shed GLP-1 program options and confirm pricing at the source (official Shed page)
Shed GLP-1 2026 Fast Facts: What Every Buyer Should Know in 60 Seconds
Shed is: A telehealth and communications platform, not a medical group or pharmacy
Prescribing is done by: Independent licensed healthcare providers in the Provider Group, not by Shed
Approval is: Not guaranteed; based solely on the Provider's clinical evaluation of your individual health profile
Compounded medications are: Not FDA-approved as finished products; prepared by licensed pharmacies on individual prescriptions
Named pharmacy partners are: Strive Compounding Pharmacy (Gilbert, AZ), Promise Pharmacy (Palm Harbor, FL), Foothills Professional Pharmacy (Tempe, AZ)
GLP-1 options include: Compounded semaglutide injections, compounded tirzepatide injections, liquid drops, lozenges, and Foundayo® (FDA-approved oral GLP-1)
Brand-name access: Wegovy® and Zepbound® are available through third-party pharmacies including LillyDirect or NovoCare after Provider approval; not sold directly by Shed
Price references: Shed product pages reference $199/month for injections or lozenges and $229/month for drops at starting doses - pricing escalates with dose and varies by program; confirm total cost at checkout on tryshed.com
Multi-month plans: Available; convert to $249/month (semaglutide) or $349/month (tirzepatide) at month-to-month after term ends
Minimum commitment: Two months, then monthly auto-renewal
Cancellation: 72 hours before billing cycle, through Member Portal
Current guarantee: 120-Day Guarantee - 5% body weight loss or full refund; four Member Commitments required; introduced June 10, 2026
Members nationwide (brand-stated): Over 150,000 - brand-stated figure based on self-reported data; not independently audited
Weight loss reported: 9.8% average per brand's VIP member self-reported data - these are brand-reported, self-attested figures, not independently verified outcomes; individual results vary and are not guaranteed
LegitScript verification: Seal displayed at tryshed.com
Insurance: Not accepted for Shed services; FSA/HSA eligibility varies by plan
Platform: 100% online intake, asynchronous or video consultation depending on state law, medication shipped directly to your door
FDA regulatory window: FDA proposed 503B compounding exclusion for semaglutide and tirzepatide on April 30, 2026 - public comment period closes June 29, 2026 - proposal not yet final - 503A patient-specific pathway remains legally active - verify current status before enrolling
Why This Update Article Exists: What Changed Between January and June 2026, and What Consumers Should Verify Before Enrolling
A prior coverage piece looked at Shed's platform in January 2026 - and if you read it, some of what you learned has since changed. Most reviews still on the first page of search results describe the old 9-month / 10% guarantee. That's grandfathered for members who enrolled before June 10. New enrollees are on a different program now. Most reviews also cite $199/month without mentioning that Shed uses a dose-escalation model - your monthly cost increases as your dose does. And almost nothing written about Shed has covered the three compounding pharmacies named with addresses in their current Terms, Foundayo's generic name (orforglipron and its April 2026 FDA approval), or the FDA's June 29 regulatory deadline.
This update covers all of it. Four changes, all material to a decision made in June 2026.
First: Shed updated its guarantee structure. The 9-month guarantee has been replaced by the 120-Day Guarantee for new enrollees starting June 10, 2026. The threshold dropped from 10% to 5% body weight loss, the window shortened from nine months to four months, and the compliance requirements changed significantly. If you're evaluating Shed partly because of the guarantee, you need the current terms, not the January terms.
Second: Shed added Foundayo® to its platform - described on the brand's site as an FDA-approved GLP-1 pill. For members who've been waiting for an oral option that carries FDA approval (rather than a compounded sublingual alternative), this is a meaningful addition. Readers should confirm Foundayo® pricing, clinical requirements, and enrollment details directly at tryshed.com's Foundayo® page and through the checkout flow.
Third: The pharmacy partners named in Shed's live Terms have changed. Shed's current Terms (§38, effective June 10, 2026) name Strive Compounding Pharmacy, Promise Pharmacy, and Foothills Professional Pharmacy as fulfillment partners. Buyers who want to research the compounding facilities dispensing their medication now have verified names and addresses from the brand's published Terms to work with.
Fourth - and most time-sensitive: the FDA published a proposed rule on April 30, 2026 proposing to exclude semaglutide and tirzepatide from the 503B Bulks List, with a public comment period closing June 29, 2026. This regulatory development affects the entire compounded GLP-1 telehealth category. The 503A patient-specific compounding pathway remains legally active, and the proposal is not yet final - but readers evaluating compounded GLP-1 programs right now are doing so during an active policy transition that no January 2026 review could have covered.
Buyer Takeaway: If you evaluated Shed based on January 2026 coverage, at minimum re-read the guarantee section at tryshed.com before subscribing - and check the current regulatory status of the compounded GLP-1 category before committing to any program. The terms and the regulatory landscape are both materially different from six months ago.
The FDA's June 29 Deadline: What Every Compounded GLP-1 Buyer Needs to Know Right Now
If you're evaluating any compounded GLP-1 program in June 2026 - including Shed's compounded semaglutide and tirzepatide options - there's a regulatory development that belongs in any complete review, and it has a deadline that's 13 days away.
On April 30, 2026, the FDA published a proposed rule in the Federal Register (docket 2026-08552, 91 Fed. Reg. 23431) proposing to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List - the regulatory mechanism that governs which active pharmaceutical ingredients large-scale compounding outsourcing facilities are authorized to use. The FDA's stated basis is that no clinical need exists for outsourcing facilities to compound these medications from bulk drug substances now that branded FDA-approved alternatives are commercially available. Public comments on that proposal are accepted through June 29, 2026. The FDA will review submitted comments before making a final determination.
This is a proposed rule. It is not yet final law. That distinction matters enormously for readers making decisions right now.
What is the difference between 503A and 503B compounding for GLP-1 medications?
Understanding this distinction is essential to evaluating any compounded GLP-1 program in 2026.
Section 503B of the Federal Food, Drug, and Cosmetic Act governs outsourcing facilities - FDA-registered operations that manufacture compounded medications in large batches for healthcare entities without individual patient-specific prescriptions. The FDA's April 30, 2026 proposal targets this pathway: if the proposal is finalized, 503B outsourcing facilities would be prohibited from compounding semaglutide, tirzepatide, and liraglutide from bulk substances under any circumstances, including in the event of a future shortage.
Section 503A governs traditional state-licensed compounding pharmacies that prepare medications for individual patients based on valid, patient-specific prescriptions. This is the pathway that telehealth platforms - including platforms like Shed that work with licensed compounding pharmacy partners - use when a licensed provider prescribes a compounded GLP-1 formulation for a specific patient. According to publicly available legal analysis of the FDA's April 30 proposal, the 503B Bulks List proposal does not directly restrict 503A pharmacies. The 503A patient-specific compounding pathway remains legally active as of the date of this publication.
However, the 503A pathway has its own legal limitations that have tightened since 2025. Per legal analysis published following the FDA's April 1, 2026 clarification, 503A compounding of semaglutide or tirzepatide may be permissible only where there is a documented, individualized medical necessity for a formulation that is not merely a copy of the FDA-approved product - such as a clinically justified need for a different concentration or a dosage form modification required for a specific patient. Patient preference and cost savings, per FDA's stated position, are not sufficient clinical justifications under the law.
Does the FDA's June 29 deadline mean compounded GLP-1 medications will be unavailable after that date?
No. June 29, 2026 is the public comment deadline - the last day for stakeholders, compounders, patient advocates, pharmacy associations, and healthcare organizations to submit written comments on the FDA's proposed rule. After that date, the FDA reviews the submitted comments and then makes a final determination. That determination could finalize the rule as proposed, modify it based on submitted comments, or withdraw the proposal. No timeline for a final determination has been publicly announced by the FDA as of this writing.
What the June 29 deadline does mean: the window for public input on the regulatory future of large-scale compounded GLP-1 access closes on that date. After the comment period closes, the trajectory toward a final determination accelerates, and the landscape for compounded GLP-1 availability through 503B outsourcing facilities becomes clearer - in whichever direction the FDA determines.
Readers relying on a compounded GLP-1 program through any telehealth platform - and readers who are evaluating whether to start one - should confirm the current regulatory and operational status of their program directly with the platform and with their prescribing provider before and after the June 29 deadline passes.
How does the FDA's proposed rule affect Shed's compounded GLP-1 programs specifically?
Shed's published Terms (§38, effective June 10, 2026) name three licensed compounding pharmacy partners: Strive Compounding Pharmacy, Promise Pharmacy, and Foothills Professional Pharmacy. These are state-licensed compounding pharmacies operating as 503A facilities - the patient-specific prescription pathway that remains legally active under current law.
The FDA's April 30, 2026 proposed rule targets the 503B outsourcing facility pathway. Shed's named pharmacy partners, as 503A facilities, are not directly addressed by the proposed 503B Bulks List exclusion. However, the broader regulatory direction - including the 503A legal standard requiring documented individualized clinical necessity, and the FDA's escalating enforcement posture across the compounded GLP-1 category throughout 2025 and 2026 - affects the legal environment in which all compounded GLP-1 programs operate.
This publication cannot determine how the FDA's final rule (once issued) will affect any specific telehealth platform's compounding pharmacy partnerships, operational model, or medication availability. Readers should confirm current program availability, regulatory compliance, and any changes to pharmacy partnerships directly with Shed through [email protected] or by reviewing tryshed.com's current product pages before enrolling.
Buyer Takeaway: June 29 is 13 days away. After that date, the FDA's regulatory direction for compounded GLP-1s becomes clearer - in whatever direction they go. The 503A patient-specific pathway is still legally active today, and Shed's named pharmacy partners operate under that framework. But this is genuinely the right moment to ask Shed directly how they're navigating the regulatory environment, before you commit to a multi-month program. That's not paranoia - it's the kind of due diligence this category now requires.
The Three-Entity Structure: Who Does What at Shed
Before anything else - before pricing, before the guarantee, before the medication formats - you should understand who's actually doing what here. Because Shed isn't a doctor's office, a pharmacy, or an insurance company. It's a technology platform that connects you to the people who are. That distinction matters, both legally and practically, so let's be clear about it.
Entity 1 - Shed Holdings, LLC (The Platform)
Shed Holdings, LLC operates tryshed.com as a telehealth and communications platform. According to Shed's published Terms and Conditions, the company "is not a medical group, does not practice medicine, and does not provide medical advice, diagnosis, or treatment." The platform provides technology infrastructure, administrative services, member support coordination, health coaching resources, and access to the Shed member portal. Shed does not prescribe medication, dispense medication, or sell medication. It does not interfere with the independent clinical judgment of the licensed providers who partner with it.
Entity 2 - The Provider Group (Independent Licensed Healthcare Providers)
All medical services - evaluations, prescriptions, treatment plans, follow-up schedules, and every clinical decision - are made exclusively by what Shed's Terms describe as "independent, physician-owned or licensed professional entities and their affiliated licensed healthcare providers." The Provider Group determines whether GLP-1 treatment is medically appropriate for you. Per Shed's Terms, "decisions regarding medical appropriateness, prescribing, modality of care (synchronous or asynchronous), eligibility for treatment, and follow-up cadence rest solely with the Provider Group and its Providers, not Shed." Prescription medication is available only after consultation and approval by a licensed healthcare provider, if clinically appropriate. Approval is not guaranteed.
Entity 3 - Licensed Compounding Pharmacies
Per Shed's Terms (§38, effective June 10, 2026), medications are fulfilled through three named licensed compounding pharmacy partners: Strive Compounding Pharmacy (1275 E Baseline Rd #104, Gilbert, AZ 85233), Promise Pharmacy (31818 US 19 S, Palm Harbor, FL 34684), and Foothills Professional Pharmacy (2727 W Baseline Rd Suite, Tempe, AZ 85283). These pharmacies are independent from Shed and from the Provider Group. They prepare and dispense compounded medication on valid prescriptions from licensed providers. Per Shed's Terms, "Shed does not control or interfere with any professional service provided by its pharmacy partners, and each is solely responsible for their provision of professional services rendered to you." Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Buyer Takeaway: Shed books the appointment. Your provider makes the call. The pharmacy fills the prescription. Those aren't just legal distinctions - they're practical ones that tell you who to contact when something goes wrong and who actually has authority over your care.
Shed's Medication Options in June 2026: What's Available
Here's what you can actually access through Shed's platform right now - and what you need to know about each option before you pick one.
Compounded GLP-1 Injections (Semaglutide and Tirzepatide)
Shed describes these on its product pages as once-weekly self-administered injections. Shed's product materials describe compounded semaglutide and tirzepatide options by reference to the active ingredients used in certain FDA-approved GLP-1 medications. However, compounded GLP-1 products are not FDA-approved as finished products, may differ in formulation, and should not be treated as equivalent to Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Shed's product pages reference a starting price from $199/month for compounded semaglutide injections at initial doses. Because Shed uses a dose-escalation pricing model - meaning monthly cost increases as your dose goes up - the starting price may not reflect what you'll pay at 3, 6, or 12 months. Always confirm your current-dose cost directly at checkout before enrolling. Compounded medications are prepared by licensed pharmacies to meet the specific needs of individual patients and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Important regulatory context: The FDA has raised specific concerns about compounded semaglutide products, including reports of adverse events (including hospitalizations) tied to dosing errors, and concerns about the use of semaglutide salt forms (sodium or acetate) rather than the semaglutide base form used in FDA-approved products. Patients considering compounded GLP-1 medications should discuss these risks with their prescribing provider and pharmacist before starting treatment.
GLP-1 Liquid Drops
According to Shed's product page, GLP-1 Liquid Drops are a sublingual form of GLP-1 therapy absorbed under the tongue, designed as a needle-free alternative. The brand describes them as taken daily rather than weekly. Shed's product pages reference a starting price from $229/month for liquid drops at initial doses. As with all Shed compounded formats, pricing may increase with dose escalation. They are a member-specific compounded formulation - not FDA-approved as finished products.
GLP-1 Lozenges (Semaglutide)
Per Shed's product page, GLP-1 Lozenges dissolve slowly under the tongue and are positioned for members seeking a needle-free format. Shed's product pages reference a starting price from $199/month for lozenges at initial doses; month-to-month terms apply, with pricing subject to dose escalation. Compounded; not FDA-approved as a finished product.
Foundayo® (orforglipron) - FDA Approved April 2026
Foundayo® - generic name orforglipron - received FDA approval in April 2026 as the first oral GLP-1 receptor agonist pill approved for weight management. Shed lists Foundayo® among its current prescription options. Shed's current homepage promotes it as "The FDA-Approved GLP-1 Pill." This product was not available during the January 2026 coverage. Foundayo® carries registered trademark status per Shed's own site notation. Pricing and clinical details should be confirmed directly on Shed's Foundayo® product page at tryshed.com, Readers should confirm Foundayo® pricing, eligibility, prescribing requirements, and pharmacy fulfillment details directly through Shed's current Foundayo® page and checkout flow. If an oral FDA-approved GLP-1 option has been the barrier keeping you from a telehealth program, that's worth exploring directly with the brand and your own provider.
Important: Foundayo® vs. Compounded GLP-1 Options. The FDA-approved status of Foundayo® applies to that specific product - it does not extend to Shed's compounded semaglutide or tirzepatide formulations. Compounded GLP-1 products remain not FDA-approved as finished products regardless of what other options Shed lists on its platform. A licensed provider must evaluate which option is clinically appropriate for your specific situation. These are meaningfully different regulatory categories and should not be conflated when comparing your options.
Wegovy® and Zepbound®
Per Shed's Terms (§11), access to brand-name FDA-approved medications Wegovy® (semaglutide) and Zepbound® (tirzepatide) is available through membership, but members purchase these directly through third-party pharmacies including LillyDirect or NovoCare after Provider approval. Shed does not sell or dispense these medications. The membership fee is separate from the cost of these brand-name medications.
Additional Options
Shed's platform also lists Metformin + Naltrexone + Topiramate, MIC + B12, and Naltrexone + Bupropion as alternative weight-loss solutions. These are not GLP-1 medications and are governed by separate clinical eligibility considerations. Verify current availability and eligibility at tryshed.com.
Buyer Takeaway: Shed now offers both compounded and FDA-approved options under the same membership umbrella. Compounded formulations are not FDA-approved as finished products. Foundayo® is the new FDA-approved oral entrant in the platform's lineup - confirm its pricing and your eligibility at tryshed.com.
The 120-Day Guarantee: The Most Important Change Since January 2026
This is the section you should read most carefully if the guarantee played any role in your interest in Shed's platform. The terms changed significantly on June 10, 2026.
What the Prior Guarantee Said (January 2026 - Now Grandfathered)
The prior guarantee required members to lose at least 10% of baseline body weight within nine months. Requirements included weekly weight logging, monthly portal check-ins, community participation (weekly Facebook community posts), all assigned learning module completions, attendance at coaching sessions, and Provider follow-up visits. Members enrolled before June 10, 2026 who are still within their nine-month window remain on the prior guarantee terms under grandfathering provisions (per Terms §16.5).
What the New 120-Day Guarantee Says (Effective June 10, 2026)
Per Shed's Terms (§16.1), effective June 10, 2026, the Shed Promise replaces the prior guarantee for new enrollees. Here's the actual structure:
Here's the threshold: Lose at least 5% of your baseline body weight OR reach the goal weight recorded at enrollment within 120 days of your Program Start Date (first medication shipment).
If you don't hit that threshold after completing all four Member Commitments, Shed will refund the total amount you actually paid to Shed during the 120-day period - including membership fees, medication cost, and any pharmacy or clinical fees collected on behalf of the Provider Group.
The four Member Commitments (all required to be eligible for the guarantee):
Attend all four monthly coaching appointments with your Shed Health Coach during the 120-day period
Log at least two weight entries per calendar month (eight total over 120 days) in the Shed Member Portal or the Pivot app
Complete at least 50% of daily Pivot check-ins - 60 out of 120 days, covering the program metrics in your member dashboard
Submit all Provider follow-up forms by their due date and remain in good standing with your treatment plan, confirmed by the Provider Group
Eligibility restrictions per Terms §16.1.2: You must be approved for treatment, remain medically eligible as determined by the Provider Group, and be a first-time user of the eligible medication class. Prior use of GLP-1 medications - compounded or brand-name - disqualifies you from the 120-Day Guarantee.
Claim window per Terms §16.1.5: Submit within 30 days after the end of your 120-day period through the Member Portal or by emailing [email protected]. Eligibility is verified from objective system records (Member Portal and Pivot logs) - not by self-attestation alone.
Per Terms §16.2: "The Shed Promise is Shed's administrative commitment with respect to Shed Program Fees only. It is not a promise on behalf of the Provider Group, any pharmacy, or any other independent third party."
What This Means Practically
The threshold dropped - from 10% to 5% body weight loss, and from nine months to four months. That's a meaningful change. But the compliance requirements are still structured and specific. You'll need to actively engage with the Pivot app, attend coaching appointments, and submit Provider follow-up forms on schedule. The guarantee doesn't fire automatically - you claim it within 30 days after your 120-day window closes.
Also notable: if your Provider directs a pause in your medication for medical reasons, the 120-day window and commitments adjust day-for-day for the pause duration per Terms §16.1.7, so a medically directed pause doesn't disqualify you.
Buyer Takeaway: The new 120-Day Guarantee is more accessible in threshold and timeline than the prior 9-month version, but it still requires documented compliance through Shed's systems. Review the full terms at tryshed.com before the guarantee becomes a deciding factor in your purchase.
Shed's Subscription and Cancellation Terms: Reading the Fine Print
The billing and cancellation sections are where real-world friction usually shows up with subscription telehealth platforms - so this is worth reading carefully. Here's what Shed's Terms (§10-13, effective June 10, 2026) actually say.
Subscription Structure
All medication programs operate as subscription-based programs that renew automatically. Billing may occur every 28 days or monthly depending on your specific program. A minimum two-month commitment applies before cancellation eligibility begins.
Dose-Escalation Pricing: The Part Most Reviews Skip
GLP-1 medications work on a titration schedule - your provider starts you low and increases your dose gradually over months, which is standard clinical practice. Shed prices its compounded GLP-1 options by dose, which means your monthly cost goes up as your dose does. The $199/month figure on Shed's product pages is a starting-dose price. Competitors in this category have documented that Shed's cost can reach $250-$299+ per month at maintenance doses. This doesn't necessarily mean the starting price is inaccurate - it means readers should understand how dose-based pricing may affect their costs at later months as their dose increases. But it means the number you see on Shed's product page may not be what you'll pay at month 4, 6, or 12. Always ask your provider what your expected dose trajectory looks like and confirm the cost at that dose before committing to a multi-month plan. Per Shed's Terms (§13.1), after a multi-month committed term ends, the standard month-to-month rate is $249/month for compounded semaglutide and $349/month for compounded tirzepatide.
Multi-Month Subscription Options
Per Terms §13.1, multi-month subscriptions are available. After the committed term ends, programs convert to month-to-month billing at the then-current standard rate - currently $249/month for compounded semaglutide and $349/month for compounded tirzepatide per the Terms. Shed gives at least 30 days' notice of any rate change (at least 7 days for California residents).
Shipment cycle for multi-month subscribers: Medications are dispensed in either one or two vial cycles per Terms §13.2. Six-month subscribers receive 24 weeks of medication total; 12-month subscribers receive 48 weeks. Partial fulfillment cycles are not available - once a shipment is dispatched, that cycle is non-refundable regardless of use, consistent with federal and state pharmacy laws prohibiting the restocking of dispensed prescription medication.
Cancellation Process
Per Terms §13.3: Log into the Member Portal → navigate to "My Treatments" → select "Cancel Subscription." Or click the cancellation link in any billing confirmation or shipment preview email. Cancellation is confirmed by email within 24 hours. Shed will not require you to complete a retention offer or additional customer-service interaction as a condition of cancellation - per the Terms, the process is direct.
Cancellation requests must be submitted at least 72 hours before your next scheduled shipment date to take effect for that cycle. Requests submitted within 72 hours of a scheduled shipment apply to the following cycle.
Note for California residents: Per Terms §13.13 and §41.3, Shed's subscription and renewal terms are designed to comply with California's Automatic Renewal Law (Business and Professions Code §17600 et seq.). California residents may cancel at any time after completing the Minimum Term through the immediate online mechanism in the Member Portal.
Refund Policy
Per Terms §11.4: Subscription fees are non-refundable once charged. Exceptions per Terms include: if a licensed Provider does not approve you for any treatment after checkout, you receive a full refund; adverse reactions resulting in Provider-directed discontinuation (§13.7); Shed-initiated changes (§13.10); and the 120-Day Guarantee refund pathway (§16.1).
Where a multi-month refund is due on cancellation, the calculation uses the month-to-month rate for used months: used months are repriced at $249 (semaglutide) or $349 (tirzepatide), and the difference from what you paid is refunded. Example from Terms §13.4: a 6-month semaglutide plan at $199/month ($1,194 paid), cancelled after 3 months with all 3 shipped - refund = $1,194 minus (3 × $249 = $747) = $447 refund.
Shipping and Pricing Disclosure
Free shipping is described on Shed's product pages. Pricing stated is starting pricing; actual cost may vary based on medication type, dose, state availability, and program selection. Tax components are calculated separately at checkout. Always confirm your final total at checkout on tryshed.com before completing any purchase. Comparison "before" prices, if any are displayed, are the brand's stated reference points and may not reflect prevailing market prices.
Buyer Takeaway: The cancellation process is portal-based and direct - the Terms explicitly prohibit requiring a retention conversation as a condition of canceling. But the 72-hour window is firm, so plan accordingly. The refund math for multi-month plans favors members who cancel early in long commitments but is not as favorable if most shipments have already gone out.
Does Shed GLP-1 Work? What Clinical Evidence and Brand-Reported Data Can and Cannot Tell You
There's a reason GLP-1 medications have taken over so much of the health conversation in the last three years. The trial results are genuinely striking. But the research is on FDA-approved medications under controlled conditions - not on any particular compounded product or telehealth program. That distinction matters, and it changes how you should read both the trial data and Shed's own reported member numbers.
Semaglutide (the active ingredient in Ozempic® and Wegovy®) was studied in the STEP trial series. STEP 1 reported that participants using semaglutide 2.4mg weekly alongside lifestyle intervention achieved approximately 15% average body weight reduction over 68 weeks, compared to approximately 2.4% with placebo plus lifestyle intervention. These figures are from a published randomized controlled trial of the FDA-approved branded drug.
Tirzepatide (the active ingredient in Mounjaro® and Zepbound®) acts on both GLP-1 and GIP receptors simultaneously. The SURMOUNT trials reported average weight reductions of approximately 20% or more in certain study populations using tirzepatide 15mg weekly.
What this clinical data does not tell you: Clinical trial outcomes for FDA-approved medications under controlled protocols do not predict results from compounded products or any telehealth service. Compounded semaglutide and tirzepatide may differ in formulation from the FDA-approved branded versions. Individual results from any GLP-1 program vary based on baseline weight, adherence, dosing, lifestyle factors, genetics, and other individual variables.
Shed reports 9.8% average weight loss from VIP member self-reported data, and 800,000+ total pounds lost across the broader member base. Those are real numbers from real people - but they're self-reported, they're not from a controlled trial, and they vary enormously depending on who you are, what medication you're on, how consistently you use it, and a dozen other factors. They're meaningful as a general signal about the platform's scale and engagement. They're not a prediction of what you'll experience. Individual results vary significantly - and your provider's evaluation of your specific situation is the only data point that actually applies to you.
Evidence Balance Note
Peer-reviewed clinical literature supports GLP-1 medications for weight management in appropriate candidates, while also documenting meaningful side effect profiles, contraindications, and weight regain following discontinuation. These medications are not appropriate for everyone, and the decision to use them should involve a licensed healthcare provider with full knowledge of your health history and current medications.
Buyer Takeaway: The clinical evidence supporting the GLP-1 drug class is substantial for FDA-approved formulations under controlled conditions. It doesn't transfer directly to compounded products or guarantee any individual result. The platform's reported outcomes are brand-self-reported and should be considered in that light.
How the Shed Platform Actually Works: The Four-Step Process
Shed describes a four-step process on its website. Here's what each step actually involves, based on the brand's published Terms and product pages.
Step 1: Complete the Online Form (5 minutes)
You fill out an online intake form covering your health history, current medications, relevant health conditions, and your preferred administration method. The accuracy of this information directly determines the quality of the Provider's evaluation. Per Shed's Terms, false or misleading health information is prohibited and can affect both clinical decisions and your account status.
Step 2: Provider Review and Approval
A licensed healthcare provider in the Provider Group reviews your submitted information. Depending on your state, this may be asynchronous (reviewing submitted information only) or may require a video consultation. Per Shed's Terms (§1), availability of asynchronous evaluation varies by state law, and that determination rests solely with the Provider Group, not with Shed. A prescription is issued only if the provider determines treatment is clinically appropriate for you. Prescription medication is available only after consultation and approval by a licensed healthcare provider, if clinically appropriate. Approval is not guaranteed.
Step 3: Medication Shipped to Your Door
If approved, your prescription is fulfilled through one of Shed's named pharmacy partners (Strive, Promise, or Foothills) or through third-party pharmacy pathways depending on the program. Per Shed's website, brand-name medications (Wegovy®, Zepbound®) are purchased directly through LillyDirect or NovoCare after Provider approval - Shed doesn't handle that fulfillment directly. Shed's product pages describe free shipping on compounded medications.
Step 4: Ongoing Support
Shed's membership includes health coaching, unlimited Provider follow-up appointments, access to the Shed Community, nutrition plans, and health courses. The platform also offers access to the Pivot app for GLP-1 injection tracking - a feature visible on the brand's current site that wasn't present in January 2026 coverage. Text-based coaching is available; per Shed's Terms, automated AI-generated responses may be included in text coaching, and all communications are monitored and reviewed by a licensed coach.
Buyer Takeaway: The process is designed to be fully digital and relatively fast. The speed variable is Provider review timing - there's no guaranteed turnaround window on Shed's product pages. If you need clinical evaluation immediately, telehealth - including Shed - may not be the right channel versus an in-person provider with appointment slots that day.
Who Shed May Be the Right Fit For
Whether Shed's the right fit for you depends on your specific situation, your priorities, and how comfortable you are with telehealth prescription services and the compounded-versus-FDA-approved distinction.
Shed may align well with people who want to explore GLP-1 treatment without scheduling in-person appointments and who live in states where Shed services are available. The platform's online-first structure removes geography as a barrier to an initial evaluation, and having a licensed provider review your profile without a video visit (in asynchronous-eligible states) can mean faster access to evaluation.
It may also suit people who prefer needle-free administration formats. Shed offers GLP-1 Liquid Drops, Lozenges, Foundayo® (oral pill), and compounded options alongside injectable alternatives - more administration format diversity than many competing telehealth platforms offer in a single membership.
If you want integrated support beyond just a prescription, Shed's membership structure includes health coaches, Member Success Managers, Pivot app access, community resources, and nutrition courses. A lot of people do better with structured accountability built into their program - and Shed's model bundles exactly that with the clinical pathway.
If you've already done the research on GLP-1 medications and you understand the compounded vs. FDA-approved distinction - including the FDA's stated concerns about semaglutide salt forms and dosing errors - Shed's compounded options offer a lower-cost entry point than brand-name Wegovy® or Zepbound®. And for those who want the FDA-approved pathway, Shed does facilitate access to Wegovy® and Zepbound® through LillyDirect and NovoCare, and now lists Foundayo® as an FDA-approved oral option.
Shed may be less well suited for people who require complex in-person medical supervision, have multiple medications that need careful interaction monitoring, are in states where Shed's preferred medication forms aren't available, or have previously used GLP-1 medications (which disqualifies you from the 120-Day Guarantee). It's also not ideal for people who want month-to-month flexibility from day one - the two-month minimum commitment is firm.
Buyer Takeaway: If you've done your GLP-1 research, understand the compounded vs. FDA-approved distinction, and want a structured program rather than just a prescription, Shed is worth a serious look. If you're still early in the research phase - this article is a reasonable starting point, but the conversation with your own doctor comes next.
Shed GLP-1 vs. Other Telehealth GLP-1 Platforms: The Honest Comparison
The telehealth GLP-1 space is crowded in 2026. Rather than comparing Shed to unnamed competitors in general terms, here are the verified differentiators that distinguish Shed's current platform based on brand-published information only.
Shed's current Terms name specific compounding pharmacy partners - Strive Compounding Pharmacy, Promise Pharmacy, and Foothills Professional Pharmacy - with full addresses. For consumers comparing telehealth GLP-1 platforms, the presence of named pharmacy partners in published Terms provides a starting point for independent due diligence on the compounding facilities that would handle your prescription.
Shed carries a LegitScript verification seal, which is an independent third-party certification that a telehealth platform operates within applicable laws and regulations. Not all GLP-1 telehealth platforms carry this certification.
Shed now lists Foundayo® (FDA-approved oral GLP-1), compounded injections, drops, and lozenges, plus access to brand-name Wegovy® and Zepbound® - a range of GLP-1 formats and regulatory pathways that consumers can compare against other platforms' current Terms and product pages.
The 120-Day Guarantee's structure is outcome-specific: 5% body weight loss or goal weight reached within 120 days, with a full refund of amounts paid during that period if the threshold isn't met. The prior 9-month / 10% guarantee required more extensive behavioral compliance and a longer timeline.
Competitors in this category should be evaluated on the same criteria: transparency about pharmacy partners, third-party platform verification, guarantee terms and conditions, cancellation process, medication form options, and the quality of ongoing clinical support. Comparing Shed's published Terms directly against a competitor's published Terms is the most defensible way to make this comparison for your own situation.
Buyer Takeaway: For consumers comparing GLP-1 telehealth platforms, Shed's current Terms provide named pharmacy partners, published guarantee rules, cancellation language, and separate disclosures for compounded versus FDA-approved options. These are useful due-diligence checkpoints to compare against any other platform's current Terms before enrolling.
The Shed Promise and the Loyalty Rewards Program: Two Incentives Worth Understanding
Beyond the 120-Day Guarantee, Shed's June 2026 Terms introduced a Loyalty Rewards Program - something that wasn't in the January coverage.
Loyalty Rewards (Terms §18)
The Loyalty Rewards Program is available to members on a compounded GLP-1 month-to-month subscription plan in good standing. Members on multi-month plans during their Minimum Term or multi-month commitment period are not eligible during that period. Here's how the milestone credits work per Terms §18.2:
At Transaction 4: $100 credit applied to that month's charge
At Transaction 8: $150 credit applied to that month's charge
At Transaction 12 and beyond: $50 monthly credit applied each subsequent month (as long as you complete a qualifying check-in each month)
Rewards are not automatic - you must complete Shed's asynchronous check-in form following the qualifying transaction. Credits are applied within 48 hours of team review. Credits are non-transferable, have no cash value, and cannot be combined with other Shed discounts or multi-month pricing. Shed reserves the right to modify or discontinue the program with 30 days' notice to active participants.
Per Terms §16.2, the Shed Promise is an administrative commitment regarding Shed Program Fees - not a commitment made by the Provider Group or any pharmacy.
Buyer Takeaway: The loyalty rewards structure benefits long-term month-to-month members who stay engaged through Shed's check-in system. If you're planning a multi-month commitment up front, you won't be eligible for loyalty rewards during that committed term - so the two programs serve different subscriber profiles.
Safety Considerations for GLP-1 Medications
GLP-1 medications are generally well-tolerated in appropriate candidates, but they carry important safety information that every prospective member should review before starting treatment. This section isn't a substitute for a conversation with your healthcare provider - it's context for that conversation.
Common side effects reported in clinical literature for GLP-1 receptor agonists include nausea (often most pronounced during dose escalation and the first several weeks of treatment), vomiting, diarrhea, constipation, headache, fatigue, and for injectable forms, injection site reactions. Most side effects are described in clinical research as transient and resolving as the body adjusts, but experiences vary significantly.
More serious considerations worth discussing with your provider before starting: GLP-1 medications carry a boxed warning in their prescribing information regarding thyroid C-cell tumors - they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Pancreatitis is a potential risk requiring monitoring. Gallbladder-related conditions have been observed in clinical trials. Hypoglycemia risk exists if GLP-1 medications are combined with certain diabetes drugs. Potential impacts on fertility and pregnancy mean these medications are generally not appropriate during pregnancy or if you're planning to become pregnant.
Specific to compounded GLP-1 products: The FDA has received reports of adverse events associated with compounded injectable semaglutide, including hospitalizations related to dosing errors. The FDA has also stated concerns about compounded products using semaglutide salt forms (sodium or acetate) rather than the semaglutide base form. Discuss the source, formulation, and dosing protocol for any compounded medication with your prescribing provider and with the dispensing pharmacy before starting treatment.
Shed's Terms (§16.1.2 and elsewhere) list a range of medical conditions that affect eligibility for treatment and for the 120-Day Guarantee, including but not limited to: personal or family history of medullary thyroid carcinoma or MEN 2, type 1 diabetes, active eating disorders, severe gastrointestinal conditions, significant kidney or liver disease, history of pancreatitis, and unmanaged psychiatric conditions. This list isn't exhaustive - your Provider will determine clinical eligibility based on your full health profile.
Drug Interaction Note: If you're taking nitrate-class cardiovascular medications, discuss potential interactions with any GLP-1 or metabolic medication with your prescribing provider and pharmacist before starting. Do not change, adjust, or discontinue any medications without your physician's guidance.
Buyer Takeaway: GLP-1 medications are clinically substantiated for weight management in appropriate candidates, but they require medical evaluation precisely because the contraindications and side effect profile are real. The telehealth intake form is your Provider's starting point - fill it out accurately.
Shed's Data Privacy and HIPAA Structure
For a telehealth service handling protected health information, understanding the data structure matters. Shed's platform involves the collection and transmission of health information through its telehealth intake and member portal systems.
Per Shed's Terms (§6) and HIPAA Notice: Shed Holdings, LLC and the Provider Group are covered by HIPAA obligations and Shed's Privacy Policy. Your protected health information is used for treatment coordination, payment, and health care operations purposes as described in the HIPAA Notice of Privacy Practices published at tryshed.com/resources/legal/hipaa-notice.
Shed's Terms (§6) note that standard SMS and similar messaging technologies may not be fully encrypted end-to-end. By using Shed's services, you consent to receiving communications via SMS; you may request confidential communication via the encrypted patient portal instead.
Text-based health coaching via Shed's platform may include automated AI-generated responses per the brand's published Terms. All such communications are described as monitored and reviewed by a licensed coach for accuracy, safety, and quality of support. AI does not replace professional medical or mental health advice per the brand's disclosure.
For questions about your specific data handling or to exercise your rights regarding your health information, review the Privacy Policy and HIPAA Notice at tryshed.com or contact [email protected].
Buyer Takeaway: Review Shed's Privacy Policy and HIPAA Notice before enrollment. If telehealth data privacy practices are important to your decision, ask data-specific questions through Shed's published support channel before entering your health information.
How to Read Shed's Marketing Language
Shed's website uses promotional language designed for consumer engagement. Here's how to interpret the most prominent claims against what the brand's own disclosures say.
"Lose 10% of your body weight or your money back" - this language refers to the prior 9-month guarantee, which is grandfathered for members who enrolled before June 10, 2026. New enrollees are on the 120-Day Guarantee (5% / 120-day threshold). Always check the guarantee section of Shed's current Terms before treating any promotional headline as a statement of your guarantee terms.
"9.83% average weight loss" (appears on some brand pages as 9.8%) - per Shed's published footnotes, this figure is from VIP member data based on self-reported weight entries. It's not a controlled trial result and isn't independently audited. Customer ratings and testimonials are brand-reported, not independently verified. Individual experiences vary.
"Over 800,000 pounds lost" - per Shed's published asterisk, this reflects self-reported data from all members, not VIP program data. It's a cumulative community figure, not a per-member average.
"150,000+ members nationwide" - brand-stated figure; not independently audited.
"Clinically-backed" - used on Shed's site to describe the platform. This refers to the platform's use of clinically studied medications and licensed provider evaluations, not to an independent clinical study of Shed's specific program outcomes.
"Foundayo® - The FDA-Approved GLP-1 Pill" - this refers to Foundayo® being an FDA-approved product; the claim about FDA approval applies to Foundayo® itself, not to Shed's platform or compounded products. Compounded products are separately not FDA-approved as finished products.
Buyer Takeaway: Promotional headlines set expectations that the fine print qualifies. The brand's own Terms and asterisked disclosures contain the material limitations. Read both before signing up.
Shed Contact Information and Support
Per Shed's published information (Terms §42, effective June 10, 2026):
Email: [email protected]
Phone: 855-694-7433 (per brand's published product pages)
Address: Shed Holdings, LLC, 10813 S River Front Pkwy, Ste 550, South Jordan, UT 84095
Official website: tryshed.com
Member portal: portal.tryshed.com
Help Center: help.tryshed.com
Pharmacy partners for questions about dispensed medications:
Strive Compounding Pharmacy: 1275 E Baseline Rd #104, Gilbert, AZ 85233
Promise Pharmacy: 31818 US 19 S, Palm Harbor, FL 34684
Foothills Professional Pharmacy: 2727 W Baseline Rd Suite, Tempe, AZ 85283
For questions about your treatment plan, contact your care team through the Shed member portal. For prescription or pharmacy questions, contact your dispensing pharmacy directly.
Regulatory and Legal Notes: What Consumers Should Understand Before Enrolling
This section exists because the GLP-1 telehealth category sits at the intersection of several active regulatory frameworks. Understanding them isn't optional - it's the context that makes everything else in this article meaningful.
This article is advertorial content with affiliate links. A commission may be earned if you purchase through links in this article, at no additional cost to you. That relationship is disclosed in accordance with FTC 16 CFR Part 255 and doesn't influence the factual content of this review. The commercial nature of this article is labeled at the top and in the disclosure bundle at the bottom.
Prescription treatment requires licensed provider evaluation. Shed is not a medical group and does not practice medicine. Independent licensed healthcare providers in the Provider Group determine whether any treatment is clinically appropriate for you. That evaluation isn't a formality - approval is not guaranteed, and some applicants won't qualify for GLP-1 treatment through this or any platform.
Compounded GLP-1 medications are not FDA-approved as finished products. FDA has raised specific concerns about compounded semaglutide, including adverse events tied to dosing errors and the use of salt forms (semaglutide sodium, semaglutide acetate) that differ from the semaglutide base in FDA-approved drugs. Consumers evaluating compounded GLP-1 options should ask their prescribing provider and dispensing pharmacy whether the medication is patient-specific, lawfully compounded, and prepared using the appropriate active pharmaceutical ingredient.
FTC endorsement rules require clear disclosure. Testimonials and outcome figures appearing in Shed's marketing reflect individual member experiences. FTC endorsement guidance requires clear disclosure of material connections and careful handling of testimonials, including clear context that individual experiences do not represent guaranteed or typical results - and this article attributes all brand-reported outcomes as brand-reported throughout.
Guarantee eligibility depends on current Terms and documented compliance. The 120-Day Guarantee has specific eligibility requirements, Member Commitments, and a claim submission window. It's not automatic. Review Section 16 of Shed's live Terms before treating the guarantee as a purchase-decision factor.
Pricing must be confirmed at checkout. Starting prices stated in this article are drawn from Shed's product pages as of June 2026. Shed's promotional landing pages may display different pricing for specific medication combinations. The only reliable price is the one you see in your checkout flow before submitting payment.
State availability and consultation format vary. Not all medication forms are available in all states. The format of your provider consultation (asynchronous vs. video) is determined by your state's telehealth laws and the Provider Group, not by Shed.
Buyer Takeaway: The strongest case for using any GLP-1 telehealth platform isn't the promotional headline - it's whether you understand who prescribes, who fulfills, what's FDA-approved versus compounded, what the guarantee actually requires, and what your total cost at checkout actually is. Every one of those answers is available in Shed's published Terms and product pages before you hand over payment information. Going in informed is the only way to evaluate any telehealth platform fairly.
The Verdict: Is Shed Worth Your Attention in June 2026?
Short answer: yes, especially if you've been sitting on this decision.
The platform is well-structured, transparent about its pharmacy partners in a way most competitors aren't, and the updated guarantee - a 5% body-weight threshold in 120 days versus the old 9-month / 10% version - is meaningfully more accessible if you're a first-time GLP-1 user who qualifies. The addition of Foundayo® (orforglipron), the first FDA-approved oral GLP-1 pill, gives people who've been avoiding compounded or injectable options a genuinely new pathway that didn't exist before April 2026.
The loyalty rewards program is a quiet bonus that month-to-month subscribers will appreciate - $100 off at month 4, $150 at month 8, and $50 every month after that, as long as you're doing the check-ins. That's real money over the course of a year.
Here's what hasn't changed and what you should still go in knowing: Shed doesn't prescribe and doesn't practice medicine - licensed providers do, independently. Compounded GLP-1 options aren't FDA-approved as finished products; FDA has raised specific concerns about salt forms and dosing errors; and the regulatory picture is actively shifting with the 503B comment period closing June 29. The two-month minimum commitment is firm. And the $199/month you see on the product page is a starting dose - confirm your actual monthly cost at checkout before you commit to a multi-month plan.
If you've already evaluated Shed and passed: the guarantee update and Foundayo® are material enough reasons to look again. If this is your first time: you're now looking at this platform with more information than most reviews provide. The right next step is a direct conversation with your own doctor and a visit to Shed's current Terms and checkout flow - not because that's a legal boilerplate line, but because your health situation, budget, and state availability are the variables that determine whether this is right for you specifically. Those questions only get answered by starting the process.
One more thing worth naming before you decide: the June 29, 2026 FDA comment deadline means the regulatory picture for compounded GLP-1 access becomes materially clearer in the next two weeks. That's not a manufactured urgency hook - it's a factual timeline with real implications. The 503A patient-specific compounding pathway remains legally active today. After June 29, the FDA's trajectory toward a final rule on 503B exclusions accelerates, and the broader legal environment for compounded GLP-1 programs will be better defined. Readers who've been sitting on a decision about a compounded GLP-1 program - any program, not only Shed - are making that decision at a moment when confirming the current status with the platform directly is more important than usual. Don't let the regulatory complexity paralyze the decision. Let it inform it.
View Shed's current pricing, guarantee terms, and take the 5-minute intake form (official Shed page)
Shed GLP-1 Frequently Asked Questions (2026 Update)
Will compounded GLP-1 medications still be available after June 29, 2026?
June 29, 2026 is the deadline for public comments on the FDA's proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List - not the date the rule takes effect. The proposal is not yet finalized. After the comment period closes, the FDA reviews submitted comments and issues a final determination on its own timeline, which the FDA has not publicly announced as of this writing. The 503A patient-specific compounding pathway - the pathway that state-licensed compounding pharmacies like Shed's named partners use - remains legally active under current law and is not directly addressed by the 503B Bulks List proposed rule. However, the broader legal environment for 503A compounding of GLP-1 medications has also tightened since 2025, with FDA and legal analysis emphasizing that 503A compounding must be based on documented individualized clinical necessity, not patient preference or cost savings alone. Readers should confirm the current operational and regulatory status of any compounded GLP-1 program directly with the platform and their prescribing provider before enrolling. Regulatory status in this category is actively changing.
What is the FDA 503B proposed rule and how does it affect Shed?
On April 30, 2026, the FDA published a proposed rule (Federal Register docket 2026-08552) proposing to permanently exclude semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that 503B outsourcing facilities - large-scale compounding operations - are permitted to use. The FDA's stated basis is that no clinical need exists for outsourcing facilities to compound these drugs from bulk now that branded FDA-approved alternatives are commercially available. If finalized, this rule would close the 503B outsourcing facility compounding pathway for these medications under any circumstances, including future shortage conditions. The public comment period closes June 29, 2026. Shed's named pharmacy partners - Strive Compounding Pharmacy, Promise Pharmacy, and Foothills Professional Pharmacy - are state-licensed 503A facilities that compound medications for individual patients on specific prescriptions, not 503B outsourcing facilities. The proposed 503B Bulks List exclusion does not directly restrict 503A pharmacies. However, the 503A pathway has its own legal requirements, and the overall regulatory direction for compounded GLP-1s is narrowing. Readers should verify the current legal and operational status of Shed's compounding pharmacy partners directly with Shed before enrolling.
Is Shed a medical provider?
No. According to Shed's Terms and Conditions (effective June 10, 2026), Shed Holdings, LLC "is not a medical group, does not practice medicine, and does not provide medical advice, diagnosis, or treatment." All medical services are provided by independent, physician-owned or licensed professional entities and their affiliated licensed healthcare providers who partner with the platform. Shed provides the technology and administrative services that facilitate the connection. Shed does not prescribe, dispense, or sell medications.
What is the current Shed guarantee?
As of June 10, 2026, new enrollees are on the Shed Promise 120-Day Guarantee: lose at least 5% of baseline body weight or reach your enrolled goal weight within 120 days of your first medication shipment. If you complete all four Member Commitments (coaching appointments, weight logging, Pivot check-ins, Provider follow-up forms) and don't hit the threshold, Shed will refund the total amount you paid to Shed during the 120-day period. The prior 9-month / 10% guarantee is grandfathered for members enrolled before June 10, 2026 who are still within their window. Verify current guarantee terms at tryshed.com.
Are Shed's compounded medications FDA-approved?
No. Compounded medications are prepared by licensed pharmacies based on individual prescriptions and are not reviewed or approved by the FDA as finished products. Shed facilitates access to both compounded formulations and FDA-approved brand-name medications (Wegovy®, Zepbound®, and Foundayo®). The FDA has raised specific concerns about compounded semaglutide products, including reports of adverse events tied to dosing errors and concerns about the use of salt forms not present in FDA-approved formulations. Discuss these distinctions with your prescribing Provider before starting treatment.
Which pharmacies fulfill Shed prescriptions?
Per Shed's Terms (§38, effective June 10, 2026), the named compounding pharmacy partners are: Strive Compounding Pharmacy (1275 E Baseline Rd #104, Gilbert, AZ 85233), Promise Pharmacy (31818 US 19 S, Palm Harbor, FL 34684), and Foothills Professional Pharmacy (2727 W Baseline Rd Suite, Tempe, AZ 85283). Brand-name medications (Wegovy®, Zepbound®) are purchased directly by members through third-party pharmacies including LillyDirect or NovoCare after Provider approval - Shed does not dispense these directly.
What is Foundayo and is it different from compounded options?
Foundayo® is promoted on Shed's current homepage as "The FDA-Approved GLP-1 Pill" - a prescription oral GLP-1 option added to Shed's platform in 2026. Unlike Shed's compounded GLP-1 formulations, which are not FDA-approved as finished products, Foundayo® carries FDA approval per the brand's description. Pricing and clinical details should be confirmed at tryshed.com, Pricing and clinical details should be confirmed directly through Shed's current Foundayo® page and checkout flow. Your Provider determines whether Foundayo® is appropriate for your clinical situation.
How much does Shed cost?
Shed's product pages list starting prices: GLP-1 Injections and GLP-1 Lozenges start at $199/month; GLP-1 Liquid Drops start at $229/month. Multi-month plans are available. After a multi-month committed term ends, subscriptions convert to the then-current month-to-month rate - currently $249/month for compounded semaglutide and $349/month for compounded tirzepatide per Shed's Terms. Membership fee is separate from medication cost; brand-name medications are purchased separately through third-party pharmacies. Shipping is described as free on product pages. Always confirm current pricing and total cost at checkout on tryshed.com before subscribing.
Can I cancel my Shed subscription?
Per Shed's Terms (§13.3), yes - via Member Portal - My Treatments - Manage Subscription, or by clicking the cancellation link in any billing confirmation email. Cancellation requires completing the two-month minimum commitment first. Requests must be submitted at least 72 hours before your next scheduled shipment to take effect for that cycle. Shed will not require a retention conversation as a condition of cancellation. California residents have additional ARL-compliant cancellation rights per Terms §13.13 and §41.3.
Does Shed accept insurance?
Shed markets programs as no insurance required. Per the platform's description, FSA and HSA funds may be used for qualifying purchases - check your specific plan for eligibility. Coverage reimbursement from third-party insurers varies; confirm directly with your insurer before purchasing.
What is the Pivot app?
Pivot is described on Shed's current homepage as a GLP-1 shot tracking app available free to Shed members. It's also referenced in the 120-Day Guarantee structure - daily Pivot check-ins are one of the four Member Commitments required for guarantee eligibility. This feature wasn't present in January 2026 coverage.
How is Shed different from seeing my doctor for GLP-1?
Shed's telehealth model allows you to get evaluated for GLP-1 treatment online, without scheduling an in-person appointment. The Provider Group evaluates your intake form rather than seeing you in person. If treatment is approved, medication ships to your door. The tradeoffs are real, though: your Provider doesn't have the benefit of a physical exam, certain conditions aren't evaluable through telehealth, and your Provider may ultimately determine that in-person care is what you actually need. For people without convenient access to in-person providers who prescribe GLP-1 medications, or for whom scheduling barriers have delayed care, the telehealth model may remove real friction. For people with complex health histories, in-person evaluation may offer meaningful additional safety.
What are the eligibility exclusions for the 120-Day Guarantee?
Per Terms §16.1.2, you must be a first-time user of the eligible medication class to qualify - prior use of any GLP-1 medication (compounded or branded) disqualifies you. You must also be approved for and remain medically eligible for treatment as determined solely by the Provider Group. Per the same Terms, your baseline weight and goal weight are locked at enrollment and cannot be changed after your Program Start Date for guarantee purposes. Consult Section 16 of Shed's live Terms at tryshed.com for the complete eligibility criteria before relying on the guarantee as a deciding factor.
Are there drug interactions I should know about with GLP-1 medications?
GLP-1 medications can interact with other medications, including certain diabetes drugs (increasing hypoglycemia risk) and medications affecting gastric emptying. If you take nitrate-class cardiovascular medications or anticoagulants, discuss potential interactions with your prescribing Provider and pharmacist before starting any GLP-1 treatment. Do not change, adjust, or discontinue any medications without your physician's guidance and approval.
What does the Shed Loyalty Rewards Program offer?
Per Terms §18, month-to-month compounded GLP-1 subscribers earn credits at milestone transaction points: $100 at Transaction 4, $150 at Transaction 8, and $50/month starting at Transaction 12 - provided you complete a qualifying check-in after each qualifying transaction. Credits are non-transferable, have no cash value, and cannot be combined with other promotions. Members on multi-month plans are not eligible for loyalty rewards during their committed term.
Is Shed available in my state?
Shed's availability varies by state, and specific medication forms may not be available in all states. Per the brand's Terms, Providers can only serve patients in states where they hold an active, unrestricted license. If you relocate after enrolling, you must inform Shed and the Provider Group promptly. Verify availability for your state at tryshed.com during the intake process.
What happened to the prior 9-month guarantee?
The prior Shed Weight-Loss Guarantee (9-month / 10% body weight loss threshold) was replaced by the Shed Promise 120-Day Guarantee effective June 10, 2026, per Terms §16.5. Members enrolled before that date who are still within their nine-month guarantee window remain grandfathered under the prior terms. Members who completed or claimed under the prior guarantee before June 10, 2026 are not affected by the transition. The Shed Promise applies to all new enrollments from June 10, 2026 onward.
What's the difference between Shed's compounded semaglutide and Wegovy?
Both contain semaglutide as the active ingredient. Wegovy® (semaglutide 2.4mg) is an FDA-approved drug that has undergone FDA review for safety, effectiveness, and manufacturing quality. Compounded semaglutide preparations made by licensed pharmacies have not undergone FDA review as finished products - they're prepared on individual prescriptions and may differ in formulation. The FDA has specifically raised concerns about compounded semaglutide products using salt forms (sodium or acetate) rather than the semaglutide base. Compounded products are generally available at lower cost than brand-name options. The right choice depends on your clinical eligibility, budget, risk tolerance, and your Provider's recommendation - it's a conversation to have during your consultation, not one that can be made from a review article.
Buyer Takeaway Summary: 15 Things to Know Before You Subscribe to Shed in 2026
Shed is a telehealth technology platform, not a medical group. The Provider Group prescribes; Shed connects.
Approval for treatment is not guaranteed - your Provider makes that determination based on your health profile.
Compounded GLP-1 medications are not FDA-approved as finished products; Foundayo® and brand-name options are FDA-approved pathways available through the platform.
The new 120-Day Guarantee (effective June 10, 2026) requires losing 5% of baseline weight or reaching your goal weight in 120 days with four specific Member Commitments completed.
If you enrolled before June 10, 2026, you're on the prior 9-month / 10% guarantee until that window closes.
First-time GLP-1 users only can access the 120-Day Guarantee - prior use disqualifies you.
Three compounding pharmacies are named in Shed's live Terms: Strive (Gilbert, AZ), Promise (Palm Harbor, FL), and Foothills (Tempe, AZ).
The two-month minimum commitment is non-negotiable from enrollment; subscription fees are non-refundable once charged except in specified circumstances.
Cancellation happens through the Member Portal - 72 hours before your next billing cycle; no retention conversation required.
LegitScript verification is displayed on tryshed.com - an independent third-party marker of compliance with telehealth legal and regulatory standards.
The Loyalty Rewards Program credits month-to-month compounded GLP-1 members at Transactions 4, 8, and 12+ - not applicable during multi-month committed terms.
Text-based coaching may include AI-generated automated responses monitored by a licensed coach, per Shed's own disclosure.
Brand-name medications (Wegovy®, Zepbound®) are purchased separately through LillyDirect or NovoCare - the membership fee doesn't cover them.
Clinical trial outcomes (15% weight loss for Wegovy®, 20% for Zepbound®) are from studies of FDA-approved products under controlled conditions - they don't predict compounded product results or any individual's outcome.
Always read Section 16 of Shed's live Terms at tryshed.com in full before treating the guarantee as a reason to subscribe.
Disclaimers and Disclosures
Content and Medical Disclaimer. This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription treatments that require evaluation by a licensed healthcare provider. The descriptions of potential benefits are not guarantees and are not a substitute for an individualized medical evaluation. Information in this article does not replace the professional judgment of your healthcare provider. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting any new prescription treatment. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval.
Compounded Medication Notice. Compounded GLP-1 medications are prepared by licensed pharmacies based on individual prescriptions. Compounded medications are not reviewed or approved by the FDA as finished products. They have not been evaluated by the FDA for safety, effectiveness, or quality before being dispensed. The FDA has raised concerns about compounded GLP-1 products, including reports of dosing errors leading to adverse events and hospitalizations, and the use of salt forms (such as semaglutide sodium or semaglutide acetate) rather than the semaglutide base form used in FDA-approved products. Brand-name options (Wegovy®, Zepbound®, Foundayo®) are FDA-approved medications that have undergone FDA review. Clinical trial outcomes for FDA-approved medications do not predict results from compounded products.
Regulatory Environment Notice. FDA policy and enforcement discretion around compounded GLP-1s has shifted as national supply conditions change; availability and fulfillment options can change. Consumers should stay informed about current regulatory guidance before making purchasing decisions.
FTC Affiliate Disclosure. This is paid advertorial content containing affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. All descriptions are based on publicly available information from Shed's official website (tryshed.com) and Shed's published Terms and Conditions (effective June 10, 2026). Affiliate relationships do not influence editorial content or the evaluation of products. Disclosure is provided in accordance with FTC 16 CFR Part 255.
Results May Vary. Individual results will vary based on factors including age, baseline weight and health condition, adherence to medication protocols, lifestyle factors, consistency of use, genetic factors, current medications, and other individual variables. Weight loss percentages cited reflect clinical trial data for FDA-approved medications under controlled protocols; they do not predict results from compounded products or any telehealth service. Potential weight loss figures are not guarantees and depend on clinical eligibility, adherence, dosing, and individual factors. Shed's self-reported member outcome figures (9.8% average weight loss, 800,000 pounds lost, 150,000 members) are brand-reported, based on self-attested member data, and are not independently audited. Customer ratings and testimonials are brand-reported, not independently verified by this publication. Individual experiences vary significantly.
Pricing Disclaimer. Starting prices cited in this article were based on information publicly available on Shed's product pages and Terms and Conditions as of June 2026 and are subject to change without notice. Shed lists starting prices by product; actual costs vary by medication type, dose, state availability, and program selection. Shipping and applicable taxes are calculated separately at checkout. Always confirm current pricing, commitment requirements, and total cost during checkout on tryshed.com before making your purchase.
Material Limitations of This Review. This review is based exclusively on publicly available materials, including the official Shed website (tryshed.com), Shed's published Terms and Conditions (effective June 10, 2026), Shed's published product pages, and category-level industry guidance on telehealth prescription platforms and GLP-1 medications. This publication has not received compensated product samples for testing, has not interviewed Shed personnel, has not been granted access to internal product specifications beyond what is publicly published, and has not conducted laboratory or field performance testing. Claims described as "according to the brand," "brand-stated," "brand-reported," or "per the brand's Terms" reflect what the brand has publicly stated and have not been independently substantiated by this publication. Buyers are encouraged to verify any claim that materially affects their purchase decision by contacting Shed directly at [email protected] or by reviewing tryshed.com. The licensed medical group operating as the Provider Group for Shed was not identified by legal entity name in Shed's published Terms as of the date of this review; references to the Provider Group use the language Shed itself publishes in its Terms.
Third-Party Consumer Feedback Platforms. This article references the existence of third-party consumer feedback in general terms only. This publication does not endorse, vouch for, audit, or accept responsibility for the accuracy, completeness, or fairness of customer reviews posted on any third-party platform, including but not limited to general-purpose review sites, social media platforms, and online discussion forums. Buyers consulting third-party reviews are encouraged to evaluate them critically, look for verified-purchase indicators where available, and weigh reviewer-specific context against their own situation.
Forward-Looking Statements and Article Accuracy. This article reflects information available as of June 2026 and was prepared using reasonable care to be accurate and useful at the time of publication. Product specifications, pricing, promotional offers, subscription terms, guarantee terms, return policies, contact information, medication availability, and pharmacy partner details may change after publication without notice. Readers should rely on the official Shed website (tryshed.com) as the authoritative source for current product information prior to any purchase decision.
Reasonable Consumer Standard. This article is written for a general adult consumer audience and intends statements to be interpreted as a reasonable consumer would interpret them in context. Where a statement could otherwise be read as a brand-substantiated fact, attribution language such as "according to the brand," "brand-stated," "brand-reported," or "per the official Terms" identifies it as a brand claim that has not been independently verified by this publication. No aggressive promotional title phrases requiring Rule 18 scaffolding apply to this release. All performance statements are brand-attributed with individual results disclaimers present throughout the article.
Subscription and Auto-Renewal Disclosure. Shed's programs are subscription-based and renew automatically. A two-month minimum commitment applies before cancellation eligibility begins. Billing occurs every 28 days or monthly depending on the specific program. Cancellation must be submitted at least 72 hours before the next billing cycle through the Member Portal. Subscription fees are non-refundable once charged, with exceptions as detailed in Shed's Terms. After a multi-month committed term, programs convert to month-to-month billing at the then-current standard rate. Review Shed's Terms (§10, §11, §13) in full at tryshed.com before subscribing.
Geographic Jurisdiction. Shed's services are available in eligible U.S. states where licensed Providers are available. Specific medication forms may not be available in all states. EU buyers should verify applicable EU consumer rights and pricing compliance requirements. Jurisdiction, medication availability, and applicable regulatory frameworks vary by location. This article does not constitute legal advice regarding any jurisdiction's laws or regulations.
California Proposition 65. California residents: Prescription medications, compounded medications, and their components may contain chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm. You have the right to verify applicable Proposition 65 warnings with your dispensing pharmacy and prescribing provider before accepting any medication. Contact Shed's pharmacy partners directly for product-specific Proposition 65 information.
Trademark Acknowledgment. Wegovy® is a registered trademark of Novo Nordisk A/S. Ozempic® is a registered trademark of Novo Nordisk A/S. Rybelsus® is a registered trademark of Novo Nordisk A/S. Zepbound® is a registered trademark of Lilly USA, LLC. Mounjaro® is a registered trademark of Lilly USA, LLC. Foundayo® is referenced as a registered trademark per Shed's brand use. Shed and tryshed.com are referenced nominatively for consumer education purposes. No affiliation with or endorsement by any trademark holder is implied by this publication. All marks are properties of their respective owners.
SOURCE: ShedRx